Literature DB >> 26649681

Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.

Kai-Lung Chen1, Chia-Chi Lin2, Yung-Tsu Cho1, Che-Wen Yang1, Yi-Shuan Sheen1, Hsiao-En Tsai3, Chia-Yu Chu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26649681     DOI： 10.1001/jamadermatol.2015.4448

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  7 in total

1.  Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?

Authors:  Yung-Tsu Cho; Kai-Lung Chen; Chia-Yu Chu
Journal:  Ann Transl Med       Date:  2016-08

2.  Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.

Authors:  Yung-Tsu Cho; Kai-Lung Chen; Yi-Shuan Sheen; Che-Wen Yang; Jau-Yu Liau; Yu-Pin Cheng; Chia-Yu Chu
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

3.  Olmutinib-induced palmoplantar keratoderma.

Authors:  K L Chen; Y T Cho; C W Yang; Y S Sheen; C W Liang; M E Lacouture; C Y Chu
Journal:  Br J Dermatol       Date:  2017-12-18       Impact factor: 9.302

Review 4.  Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Authors:  Chia-Yu Chu; Jennifer Choi; Beth Eaby-Sandy; Corey J Langer; Mario E Lacouture
Journal:  Oncologist       Date:  2018-04-12

5.  Afatinib-Associated Cutaneous Toxicity: A Correlation of Severe Skin Reaction with Dramatic Tumor Response in a Woman with Exon 19 Deletion Positive Non-Small-Cell Lung Cancer.

Authors:  Lindsay P Osborn; Philip R Cohen
Journal:  Cureus       Date:  2016-09-01

6.  Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report.

Authors:  Xiao Shen; Guorong Fan; Gaolin Liu; Fan Wang; Qi Li; Xinyan Liu; Hong Zhu; Ying Zhu; Jiguang Lu; Shuowen Wang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

7.  Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.

Authors:  Youjin Kim; Se-Hoon Lee; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Jong-Mu Sun
Journal:  Cancer Res Treat       Date:  2018-06-13       Impact factor: 4.679
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.